Suppr超能文献

评估 PNU-159682 抗体药物偶联物(ADCs)。

Evaluation of PNU-159682 antibody drug conjugates (ADCs).

机构信息

AbbVie Chemical Development & Manufacturing, 995 East Arques Avenue, Sunnyvale, CA 94085, USA.

Enliven Therapeutics, 6200 Lookout Road, First Floor, Boulder, CO 80301, USA.

出版信息

Bioorg Med Chem Lett. 2020 Dec 15;30(24):127640. doi: 10.1016/j.bmcl.2020.127640. Epub 2020 Oct 28.

Abstract

PNU-159682 is a highly potent secondary metabolite of nemorubicin belonging to the anthracycline class of natural products. Due to its extremely high potency and only partially understood mechanism of action, it was deemed an interesting starting point for the development of a new suite of linker drugs for antibody drug conjugates (ADCs). Structure activity relationships were explored on the small molecule which led to six linker drugs being developed for conjugation to antibodies. Herein we describe the synthesis of novel PNU-159682 derivatives and the subsequent linker drugs as well as the corresponding biological evaluations of the small molecules and ADCs.

摘要

PNU-159682 是一种属于蒽环类天然产物的强力霉素次级代谢产物。由于其极高的效力和部分未知的作用机制,它被认为是开发新型抗体药物偶联物 (ADC) 连接子药物的一个有趣起点。对小分子进行了结构活性关系研究,从而开发了六种用于与抗体结合的连接子药物。本文描述了新型 PNU-159682 衍生物及其随后的连接子药物的合成,以及小分子和 ADC 的相应生物学评价。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验